Antagonists of growth-hormone-releasing hormone: An emerging new therapy for cancer

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 1, 2008, Pages 33-43

  Schally, Andrew V ^a,b   Varga, Jozsef L ^b   Engel, Jörg B ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cancer; GHRH antagonists; GHRH receptors; Tumor growth inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE RELEASING FACTOR RECEPTOR; JMR 132; JV 1 36; JV 1 38; JV 1 63; JV 1 65; JV 1 68; MZ 4 71; MZ 5 156; MZ J 7 110; MZ J 7 114; MZ J 7 118; MZ J 7 138; MZ J 7138; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOSTATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; COLORECTAL CARCINOMA; DIABETIC RETINOPATHY; DNA SEQUENCE; DRUG MECHANISM; ENDOMETRIUM CANCER; ERYTHEMA; HOT FLUSH; HUMAN; KIDNEY CANCER; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STOMACH CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37349032876     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0677     Document Type: Review

References (81)

1. Schally AV et al. (1965) Effect of hypothalamic extracts on release of growth hormone in vitro. Proc Soc Exp Biol Med 119: 208-212
2. Krulich L et al. (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83: 783-790
3. Frohman LA and Szabo M (1981) Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res 74: 259-271
4. Guillemin R et al. (1982) Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218: 585-587
5. Rivier J et al. (1982) Characterization of a growth hormone-releasing factor from a human pancreatic islet tumor. Nature 300: 276-278
6. Muller EE et al. (1999) Neuroendocrine control of growth hormone secretion. Physiol Rev 79: 511-607
7. Gelato MC (1994) Growth hormone-releasing hormone: clinical perspectives. Endocrinologist 4: 64-68
8. Bagnato A et al. (1992) Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology 130: 1097-1102
9. Chatzistamou I et al. (2004) Immunohistochemical detection of growth hormone-releasing hormone and its receptor splice variant 1 in primary human breast cancers. Eur J Endocrinol 151: 391-396
10. Freddi S et al. (2005) Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours. Clin Endocrinol 62: 533-538
11. Halmos G et al. (2002) Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 87: 4707-4714
12. Kahan Z et al. (1999) Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84: 582-589
13. Khorram O et al. (2001) Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions. Fertil Steril 75: 174-179
14. Busto R et al. (2002) The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci U S A 99: 11866-11871
15. Busto R et al. (2002) Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors. Regul Pept 108: 47-53
16. Chopin LK and Herington AC (2001) A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 49: 116-121
17. Engel JB et al. (2005) Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 90: 3614-3621
18. Garcia-Fernandez MO et al. (2003) The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 77: 15-26
19. Kanashiro CA et al. (2003) Inhibition of mutant P53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci U S A 100: 15836-15841
20. Havt A et al. (2005) The expression of the pituitary GHRH receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A 102: 17424-17429
21. Keller G et al. (2005) Effective treatment of experimental human non Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A 102: 10628-10633
22. Khorram O et al. (2001) The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system. J Clin Endocrinol Metab 86: 3157-3161
23. Kiaris H et al. (1999) Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci U S A 96: 14894-14898
24. Plonowski A et al. (2002) Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides 23: 1127-1133
25. Szereday Z et al. (2003) Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res 63: 7913-7919
26. Losa M et al. (1990) Presence of growth hormone-releasing hormone-like immunoreactivity in human tumors: characterization of immunological and biological properties. J Clin Endocrinol Metab 70: 62-68
27. Kiaris H et al. (2003) Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc Nat Acad Sci U S A 100: 9512-9517
28. Schally AV and Varga JL (1999) Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab 10: 383-391
29. Rekasi Z et al. (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 97: 10561-10566
30. Kiaris H et al. (2005) Extrapituitary effects of the growth hormone-releasing hormone. In Vitamins and Hormones, 1-24 (Ed. Litwack G) Amsterdam: Elsevier
31. Toller GL et al. (2004) Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. Proc Natl Acad Sci U S A 101: 15160-15165
32. Halmos G et al. (2000) Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci U S A 97: 10555-10560
33. Kanashiro CA et al. (2007) Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol 30: 1019-1028
34. Chatzistamou I et al. (2001) Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 12: 761-768
35. Kiaris H et al. (2000) Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2: 242-250
36. Schulz S et al. (2006) Immunocytochemical localisation of plasma membrane GHRH receptors in human tumours using a novel anti-peptide antibody. Eur J Cancer 42: 2390-2396
37. Barabutis N et al. (2007) Ligand dependent and independent stimulation of proliferation of MCF-7 breast cancer cells by a splice variant of growth hormone releasing hormone receptor. Proc Natl Acad Sci U S A 104: 5575-5579
38. Westley BR and May FEB (1995) Insulin-like growth factors: the unrecognized oncogenes. Br J Cancer 72: 1065-1066
39. Toretsky JA and Helman LJ (1996) Involvement of IGF-II in human cancer. J Endocrinol 149: 367-372
40. Pollak MN et al. (1990) Insulin-like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82: 301-305
41. Pollak M et al. (1992) Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84: 966-971
42. Robberecht P et al. (1985) Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology 117: 1759-1764
43. Zarandi M et al. (1994) Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A 91: 12298-12302
44. Zarandi M et al. (1997) Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 18: 423-430
45. Schally AV and Varga JL (2006) Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen 9: 163-170
46. Varga JL and Schally AV (2006) Analogues of growth hormone-releasing hormone (GH-RH) in cancer. In Handbook of Peptides, 483-489 (Ed. Kastin A) London: Elsevier
47. Kovács M et al. (1997) Inhibition of GH release in rats by new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 18: 431-438
48. Varga JL et al. (1999) Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci U S A 96: 692-697
49. Varga JL et al. (2004) Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9 and 10. Proc Natl Acad Sci U S A 101: 1708-1713
50. Zarandi M et al. (2006) Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proc Natl Acad Sci U S A 103: 4610-4615
51. Buchholz S et al. (2007) Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci U S A 104:1943-1946
52. Stangelberger A et al. (2007) The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. Prostate 67: 1339-1353
53. Stangelberger A et al. (2005) Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and EGF/HER receptors in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 64: 303-315
54. Stangelberger A (2005) Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 11: 49-57
55. Csernus VJ et al. (1999) Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci U S A 96: 3098-3103
56. Braczkowski R et al. (2002) Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing's sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on IGF-II. Cancer 95: 1735-1745
57. Letsch M et al. (2004) Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumor growth inhibition induced by androgen deprivation in human MDA-PCa-2b prostate cancers. Eur J Cancer 40: 436-444
58. Szepeshazi K et al. (2001) Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 142: 4371-4378
59. Letsch M et al. (2003) Growth hormone-releasing hormone (GH-RH) antagonists inhibit the proliferation of androgen- dependent and -independent prostate cancers. Proc Nat Acad Sci U S A 100: 1250-1255
60. Hohla F et al. (2006) Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci U S A 103: 14513-14518
61. Chatzistamou I et al. (2001) Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 86: 2144-2152
62. Pinski J et al. (1996) Inhibition of growth of human small-cell and non-small-cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol 9: 1099-1105
63. Szepeshazi K et al. (2000) Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors. Eur J Cancer 36: 128-136
64. Szepeshazi K et al. (2000) Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Brit J Cancer 82: 1724-1731
65. Jaffe CA et al. (1993) Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest 92: 695-701
66. Hanew K et al. (1996) Plasma GH responses to human GHRH-antagonist in normal subjects. Eur J Endocrinol 134: 67-72
67. Ocampo-Lim B et al. (1996) Nocturnal growth hormone (GH) secretion is eliminated by infusion of GH-releasing hormone antagonist. J Clin Endocrinol Metab 81: 4396-4399
68. Hanew K et al. (1996) The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-DOPA, and clonidine-induced GH secretion in normal subjects. J Clin Endocrinol Metab 81: 1952-1955
69. Russell-Aulet M et al. (1999) In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab 84: 3490-3497
70. Orrego JJ et al. (2001) Semiquantification of hypothalamic GH-releasing hormone output in women: evidence for sexual dimorphism in the mechanism of the somatopause. J Clin Endocrinol Metab 86: 5485-5490
71. Jessup SK et al. (2003) Sexual dimorphism of growth hormone (GH) regulation in humans: endogenous GH-releasing hormone maintains basal GH in women but not in men. J Clin Endocrinol Metab 88: 4776-4780
72. Jessup SK et al. (2004) Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol 151: 561-566
73. Jaffe CA et al. (1996) Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. J Clin Invest 97: 934-940
74. Jaffe CA et al. (1997) Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. J Clin Endocrinol Metab 82: 634-637
75. Dimaraki EV et al. (2006) The role of endogenous growth hormone-releasing hormone in acromegaly. J Clin Endocrinol Metab 91: 2185-2190
76. Gelato M (2005) Growth hormone releasing hormone: clinical perspectives revisited. Endocrinologist 15: 159-164
77. Smith LE et al. (1997) Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276: 1706-1709
78. Reddy GR et al. (2007) Identification of the glomerular podocyte as a target for growth hormone action. Endocrinology 148: 2045-2055
79. Stephanou A et al. (1991) Production of a growth hormone-releasing hormone-like peptide and its mRNA by human lymphocytes. Neuroendocrinology 53: 628-633
80. Guarcello V et al. (1991) Growth hormone releasing hormone receptors on thymocytes and splenocytes from rats. Cell Immunol 136: 291-302
81. 2 administration on the immune system of aging men and women. J Clin Endocrinol Metab 82: 3590-3596